AAAAI President Featured in USA Today “Asthma & Allergies” Supplement
AAAAI President, David B. Peden, MD, MS, FAAAAI, was featured in an article in the USA Today Supplement “Asthma & Allergies.” His foreword included information on the prevalence of allergic disease and emphasized the benefits of seeing a board certified allergist/immunologist. To view the article, click here.
AAAAI Fellow Leads Study Investigating Cancer Drug as Asthma Treatment
In a recent study in the New England Journal of Medicine (NEJM), lead investigator Elliot M. Israel, MD, FAAAAI, and his team looked into the possibility of using the cancer drug imatinib, commonly called Gleevec, as a possible treatment for severe refractory asthma. Patients on imatinib with severe asthma had decreased airway hyperresponsiveness, mast-cell counts and tryptase release compared to the placebo group. The study involved 62 patients. Half of the patients were treated with the drug and 8 of those patients dropped out. To learn more, read the article on STAT or view the article “KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma” on NEJM’s website.
- Be Aware of the Fluticasone Propionate Nasal Spray Recall and Shortage of Sterile Water for Injection
- You Can Now View Recordings from the 2018 AAAAI/WAO Joint Congress
- Get Practice Management Tips while Networking with Colleagues from across the Country
- Want to Dive Deeper into Your Research?
- AAAAI’s Hands-on Training Stations Recognized in ACCME Newsletter
- View This Month’s Featured Careers